Skip to main content

Table 1 Inhibition of the incidence and mean score of CIA by treatment with AMD3100

From: Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis

Experiment number Treatmenta Cumulative incidence (%) Score of arthritis (mean ± SEM)
   Start of treatmentb End of treatmentc All miced Arthritic mice onlye
1 AMD3100 2/10 (20%) 3/10 (30%)f 1.4 ± 0.9f 4.7 ± 2.4
  Control 2/12 (17%) 9/12 (75%) 5.2 ± 0.9 6.2 ± 0.6
2 AMD3100 1/7 (14%) 2/7 (29%) 0.9 ± 0.6f 3.0 ± 1.0
  Control 2/7 (29%) 5/7 (71%) 2.4 ± 0.8 3.4 ± 0.7
3 AMD3100 2/8 (25%) 2/8 (25%)g 0.6 ± 0.5g 2.5 ± 1.5
  Control 1/8 (13%) 7/8 (88%) 3.9 ± 1.4 4.3 ± 1.5
  1. The table shows the results of three individual experiments. Male mice were immunized with collagen type II/complete Freund's adjuvant on day 0. aAt the day first symptoms appeared (day 27 in experiment 1 and 2, day 24 in experiment 3), mice were divided into two groups and were implanted with osmotic minipumps delivering AMD3100 at a constant rate of 600 μg/day or PBS in the control groups. Distribution of the mice between the two groups was done in a way that an equal incidence and a similar clinical score was reached in both groups. bArthritic incidence in both groups at the start of the treatment is shown. cAt the end of the treatment, there was a significant inhibition of the incidence in the AMD3100-treated group compared to the control in experiments 1 and 3 (fp < 0.05 and gp < 0.01, respectively; binomial proportion test). dAt the end of the treatment, the mean arthritic scores calculated for all mice were significantly different between the AMD3100-treated and control groups for all the three experiments (fp < 0.05 for experiments 1 and 2; gp < 0.01 for experiment 3; Mann-Whitney U-test). eAt the end of the treatment, the mean arthritic scores calculated for mice with symptoms of arthritis were not significantly different between the AMD3100-treated and control groups. SEM, standard error of the mean.